⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRSP News
CRISPR Therapeutics AG
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
globenewswire.com
CRSP
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
globenewswire.com
CRSP
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
globenewswire.com
CRSP
Australia’s Largest University Establishes ‘Monash Boston Hub’ to Accelerate Global Biotech Partnerships and Licensing
businesswire.com
CRSP
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
globenewswire.com
CRSP
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
prnewswire.com
TEM
CRSP
BNTX
BMY
TEM
CRSP
BNTX
BMY